Jasper Therapeutics, Inc. filed a Form 8-K on November 9, 2026, announcing the results of its completed offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering.

Key Highlights

  • Offer closed: The warrant tender offer expired at 12:00 a.m., Eastern Time, on November 7, 2026.
  • Purchase price: Jasper Therapeutics offered $0.324 in cash per warrant, without interest, according to the filing.
  • Warrants targeted: The offer covered all outstanding warrants to purchase shares of common stock (par value $0.0001) issued as part of the September 18, 2025 underwritten public offering.
  • Results announced: The company issued a press release on November 9, 2026 disclosing the results, filed as Exhibit 99.1.
  • Signed by: The filing was signed by Jeet Mahal, Chief Executive Officer.

Jasper Therapeutics Completes Warrant Repurchase Tied to 2025 Public Offering

Jasper Therapeutics, Inc. (NASDAQ:JSPR) disclosed via a current report filed November 9, 2026 that it had completed a tender offer to purchase all of its outstanding warrants originally issued in connection with an underwritten public offering on September 18, 2025. According to the filing, the company offered $0.324 in cash per warrant, with no interest, and the offer expired at 12:00 a.m., Eastern Time, on November 7, 2026.

The filing was made under Item 8.01 (Other Events) and indicates the warrants were for the purchase of shares of common stock with a par value of $0.0001 per share. The company disclosed that a press release detailing the results of the offer was issued on November 9, 2026, and that press release was incorporated by reference into the filing as Exhibit 99.1.

The report was signed on behalf of the registrant by Jeet Mahal, Chief Executive Officer, on November 9, 2026. The company is incorporated in Delaware and is headquartered at 2200 Bridge Pkwy Suite #102, Redwood City, CA 94065. The filing does not indicate that Jasper Therapeutics qualifies as an emerging growth company.

What Was Disclosed

Jasper Therapeutics reported the completion of a cash tender offer for all outstanding warrants from its September 2025 public offering at $0.324 per warrant, with the offer expiring on November 7, 2026, and results announced via press release on November 9, 2026.